Home > Boards > US OTC > Biotechs >

Talon Therapeutics, Inc. (TLON)

TLON RSS Feed
Add TLON Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/21/2021 9:44:26 PM - Followers: 93 - Board type: Free - Posts Today: 0

 

 



is since dec. 2010



 

Company Overview

Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - http://maps.yahoo.com/maps_result?addr=2207%20Bridgepointe%20Parkway%20Suite%20250&csz=San%20Mateo%20CA%2094404&country=United%20States" rel="nofollow">Map
Phone:                650-588-6404       
Fax: 650-588-2787
Website: http://www.talontx.com
 

Business Summary  

Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California

   

Current Pipeline

 

 



Overview

Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »
 





Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »

Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »

Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »


Presentations


Presentations
Talon Therapeutics Corporate Presentation   PDF 869.6 KB Add to Briefcase


Publications
VSLI (Vincristine Sulfate Liposomes Injection, Marqibo®) "Bridging" to Potentially Curative Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Philadelphia Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) 06/09/2011 PDF 151.1 KB Add to Briefcase
VSLI (vincristine sulfate liposomes injection) in the Treatment of Adult Subjects with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and rALLy Studies 12/05/2010 PDF 110.6 KB Add to Briefcase
Marqibo (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) 12/05/2010 PDF

and more:

http://ir.talontx.com/presentations.cfm




INFOS
 

  • OTC Market Tier

    Pink Quote/OTCBB
  • Primary SIC - Industry Classification

    2834 - Pharmaceutical preparations
  • State Of Incorporation

    DE
  • Jurisdiction Of Incorporation

    United States

      

     

Board of Directors

Steven R. Deitcher, M.D.
President & Chief Executive Officer


Nishan de Silva, M.D.
Principal, Warburg Pincus

Andrew K. Ferrer
Associate, Warburg Pincus

Howard P. Furst, M.D.
Partner, Deerfield Management

Jonathan S. Leff
Managing Director, Warburg Pincus

Paul V. Maier
Chief Financial Officer, Sequenom, Inc.

Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University

Robert J. Spiegel, M.D.
Director

 

  • SEC Reporting Status

    SEC Reporting Company
  • CIK

    0001140028
  • Fiscal Year End

    12/31

Current Share Structure

Current as of 12/31/2010

A/S 350,000,000

O/S 21,242,772 (Mar 28, 2011)

FLOAT  16.48M

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209

 


 Recent news

 

Tuesday, August 9, 2011

Wednesday, July 20, 2011

Tuesday, July 19, 2011

Monday, July 18, 2011

Friday, July 1, 2011

Thursday, June 30, 2011

Friday, June 17, 2011

Monday, June 6, 2011

Thursday, May 19, 2011

Friday, May 13, 2011

Tuesday, May 10, 2011

Monday, May 9, 2011

Monday, March 28, 2011

Thursday, March 24, 2011

Monday, March 14, 2011

Thursday, March 10, 2011

Wednesday, January 12, 2011

   
   
   
   
   
   


Charting


 

 

New presentation from tlon from 3-30-12

http://files.shareholder.com/downloads/HNAB/1722627662x0x556820/A59F1E05-C4F6-4235-B039-7B3CCE775B48/talontx_corp_pres.pdf

TLON
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#6070   We all know that is legal or illegal FLY HIGH NOW 11/21/21 09:44:26 PM
#6069   Td Ameritrade took it off from my account xlofer 11/19/21 08:44:59 PM
#6068   Hello All TLON investors FLY HIGH NOW 11/19/21 03:19:26 PM
#6067   We appreciate your responses FLY HIGH NOW 11/08/21 05:32:02 PM
#6066   I think the Talon rights should remain at operating_line 11/06/21 05:55:28 AM
#6065   Latest from CASI Pharmaceuticals operating_line 11/06/21 05:42:23 AM
#6064   FDA’s accelerated approval program: Is change on the way? operating_line 11/06/21 05:39:36 AM
#6063   Hello to all CVRs Holders of our Hard FLY HIGH NOW 09/22/21 07:37:18 PM
#6062   Hello Tlon investors FLY HIGH NOW 07/12/21 12:59:32 PM
#6061   Hi Operating-line FLY HIGH NOW 04/05/21 03:44:54 PM
#6060   Equiniti Acquires Corporate Stock Transfer To Expand In US operating_line 03/21/21 01:52:37 AM
#6059   Hi Operating Line FLY HIGH NOW 03/19/21 02:23:06 AM
#6058   Any Tlon investors heard/ saw any our CVRs FLY HIGH NOW 03/02/21 10:36:16 AM
#6057   Okay. Let us know if you succeed to operating_line 01/31/21 03:23:45 AM
#6056   Hi Operating Line CVR Investor 01/30/21 12:02:42 AM
#6055   I think if you do not have you operating_line 01/16/21 12:53:45 AM
#6054   Happy New Year ?????? FLY HIGH NOW 01/14/21 02:08:08 PM
#6053   Happy New Year ?????? FLY HIGH NOW 01/14/21 02:08:07 PM
#6052   As mentioned, no payout for TLON CVRs has operating_line 11/16/20 07:42:28 AM
#6051   Hello Operating FLY HIGH NOW 11/16/20 12:44:46 AM
#6050   this is back to you. please add pressure operating_line 11/12/20 09:54:57 AM
#6049   I just got a response. There should be operating_line 11/12/20 09:53:27 AM
#6048   Thanks If any TLON investors have any update about FLY HIGH NOW 11/12/20 09:49:54 AM
#6047   No response. operating_line 11/12/20 08:36:12 AM
#6046   Hello operating line FLY HIGH NOW 11/10/20 10:12:45 AM
#6045   Thanks sir FLY HIGH NOW 10/14/20 12:14:26 AM
#6044   yes, they absorbed the agent that handled the operating_line 10/13/20 05:14:06 AM
#6043   Equinity now should have all docs related to FLY HIGH NOW 10/12/20 01:06:58 PM
#6042   CST is now part of Equiniti operating_line 10/12/20 09:19:41 AM
#6041   Corporate Stock Transfer inc. was first our Transferring FLY HIGH NOW 10/12/20 08:52:22 AM
#6040   I will update if any response from Equiniti. operating_line 10/11/20 11:01:41 PM
#6039   We all TLON shareholders should Call Transfering Agent FLY HIGH NOW 10/11/20 06:00:22 PM
#6038   I think it was 0.05 per share. I operating_line 10/11/20 01:21:43 AM
#6037   We would like to know when M&A agreements FLY HIGH NOW 10/10/20 02:09:20 PM
#6036   It appears from your message that the CVRs operating_line 10/10/20 02:21:12 AM
#6035   We talked to manager Travis Carroll ( 800-661-4587)who FLY HIGH NOW 10/09/20 01:37:37 PM
#6034   yes, please try that way first. operating_line 09/25/20 11:21:05 AM
#6033   Thanks, We may call and talk to E*TRADE again FLY HIGH NOW 09/25/20 11:12:55 AM
#6032   It does not smell right. operating_line 09/25/20 12:03:18 AM
#6031   Hello there FLY HIGH NOW 09/24/20 11:30:12 PM
#6030   I think the first step is to ask operating_line 09/23/20 09:44:36 AM
#6029   If we Tlon investors have new agent for FLY HIGH NOW 09/23/20 01:26:19 AM
#6028   TLON CVRs are now with a new agent, Equiniti operating_line 09/14/20 10:26:16 AM
#6027   Did you ever find out why they took CVR Investor 08/25/20 09:17:05 AM
#6026   We all TLON investors can seek Helps from FLY HIGH NOW 06/24/20 06:09:20 PM
#6025   best chance is something from CASI first in China operating_line 06/18/20 12:11:35 AM
#6024   Previously I saw May 2021 for clinical trials operating_line 06/17/20 11:47:11 PM
#6023   Okay, I see what you mean. I still CVR Investor 06/17/20 05:31:01 PM
#6022   We need to see a milestone being met operating_line 06/12/20 11:44:40 PM
#6021   I think we should call the SEC. I CVR Investor 06/12/20 12:30:43 PM
PostSubject
Consent Preferences